IP Library Granted Patent US 10,874,658
Granted Patent B2
US 10,874,658 · App. 16/299,444 · Granted Dec 29, 2020

Sublingual opioid formulations containing naloxone

Inventors: Ning Shan (Chandler, AZ); Rajesh R. Wakaskar (Chandler, AZ); Edwin A. Baldwin (Tempe, AZ); Andrew B. Schlinkert (Scottsdale, AZ); Min Wu (Chandler, AZ); Ningxin Yan (Chandler, AZ)
Assignee: HIKMA PHARMACEUTICALS USA INC.
A61K31/4468A61K9/006A61K31/485A61K47/10A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,658
App. No.
16/299,444
Granted
Dec 29, 2020
Kind
B2
Abstract

Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.

Claims (20)

1. A sublingual hydroalcoholic formulation comprising:

an opioid selected from the group consisting of alfentanil, butorphanol, codeine, diamorphine, dextromoramide, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, meptazinol, methadone, morphine, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl, sufentanyl, tapentadol, and tramadol, and pharmaceutically acceptable salts thereof;

an alcohol;

propylene glycol; and

naloxone or a pharmaceutically acceptable salt or ester thereof, and/or a terpene, wherein the formulation is suitable for sublingual administration.

2. The formulation of claim 1 , wherein the opioid is fentanyl.

3. The formulation of claim 1 , wherein the terpene is selected from the group consisting of menthol, limonene, linalool, cineole, nerolidol, farnesol, geraniol, carvone, terpinolene, and ascaridole.

4. The formulation of claim 1 wherein the terpene is menthol.

5. The formulation of claim 1 , wherein the alcohol is ethanol.

6. The formulation of claim 1 , wherein the opioid is present at a concentration from 0.1% to 2% weight by weight of the total formulation.

7. The formulation of claim 1 , wherein naloxone or the pharmaceutically acceptable salt or ester thereof is present at a concentration from 0.01% to 20% weight by weight of the total formulation.

8. The formulation of claim 7 , wherein naloxone or the pharmaceutically acceptable salt or ester thereof is present at a concentration from 0.1% to 1.6% weight by weight of the total formulation.

9. The formulation of claim 1 wherein propylene glycol is present at a concentration from 1% to 10% weight by weight of the total formulation.

10. The formulation of claim 9 , wherein propylene glycol is present at a concentration from 4% to 6% weight by weight of the total formulation.

11. The formulation of claim 5 , wherein ethanol is present at a concentration from 20% to 80% weight by weight of the total formulation.

12. The formulation of claim 11 , wherein ethanol is present at a concentration from 40% to 60% weight by weight of the total formulation.

13. The formulation of claim 4 , wherein the concentration of menthol is from 0.1% to 10% weight by weight of the total formulation.

14. The formulation of claim 13 , wherein the concentration of menthol is 0.05% to 0.5% weight by weight of the total formulation.

15. The formulation of claim 1 further comprising xylitol.

16. A method of treating pain comprising administering to a patient in need thereof a therapeutically effective amount of a formulation of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2019
From: BALDWIN, EDWIN A.
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 051324/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: INSYS DEVELOPMENT COMPANY, INC.
To: HIKMA PHARMACEUTICALS USA INC.
Reel/Frame 050346/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2019
From: WAKASKAR, RAJESH; WU, MIN; YAN, NINGXIN
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 050298/0034 →